Cited by 182Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

Tu, Hai-Yan, Ke, E-E, Yang, Jin-Ji, Sun, Yue-Li, Yan, Hong-Hong, Zheng, Ming-Ying, Bai, Xiao-Yan, Wang, Zhen, Su, Jian, Chen, Zhi-Hong, Zhang, Xu-Chao, Dong, Zhong-Yi, Wu, Si-Pei, Jiang, Ben-Yuan, Chen, Hua-Jun, Wang, Bin-Chao, Xu, Chong-Rui, Zhou, Qing, Mei, Ping, Luo, Dong-Lan, Zhong, Wen-zhao, Yang, Xue-Ning, Wu, Yi-Long·2017·Lung Cancer

DOI 10.1016/j.lungcan.2017.11.005

Open this paper in CoChat — free account

Abstract

Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting differential responses to EGFR inhibitors. This retrospective study reviews the prevalence of uncommon EGFR mutations in a Chinese NSCLC cohort and the clinical characteristics and efficacy of EGFR tyrosine kinase inhibitors (TKIs) associated with these patients.Materials andmethods A total of 5363 lung cancer patients were screened and underwent EGFR genotyping at the Guangdong Lung Cancer Institute. Of those with uncommon EGFR mutations, the clinical characteristics and responses to EGFR-TKIs were reviewed retrospectively.Results Uncommon EGFR mutations were observed in 218 patients, comprising 11.9% of all patients with documented EGFR mutations. More smokers (30.7% vs. 24.3%, P=0.039) and males (54.1% vs. 44.4%, P=0.007) were among the patients with uncommon mutations compared with common mutations. The most frequent uncommon mutations were exon 20 insertions (30.7%, n=67), followed by G719X mutations (21.1%, n=46) and compound L858R mutations (17.0%, n=37). Favorable efficacy was observed in patients harboring compound L858R or G719X mutations, with a median progression-free survival (PFS) of 15.2 (95% CI: 8.7-21.7) or 11.6 (95% CI: 3.6-19.6) months, respectively. The median PFS of those with the T790M mutation or an exon 20 insertion was 1.0 (95% CI: 0.0-2.2) and 3.0 (95% CI: 1.3-4.7) months, respectively.Conclusion This study reviewed the prevalence of uncommon EGFR mutations and their sensitivity to EGFR-TKIs. Favorable responses were observed in patients with G719X and compound L858R mutations, indicating that they may benefit from EGFR-TKIs as a first-line therapy.

Integrity signals

Registry

Crossref · 10.1016/j.lungcan.2017.11.005

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citation
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citation
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Self-citation
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Shi, Y., Au, J. S. K., Thongprasert, S., Srinivasan, S., Tsai, C., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G. H., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,575
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
Yang, J. C.-H., Sequist, L. V., Geater, S. L., Tsai, C.-M., Mok, T. S. K., Schuler, M., Yamamoto, N., Yu, C.-J., Ou, S.-H. I., Zhou, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00026-1 · Cited by 1,002
Self-citation
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Wu, Y.-L., Zhou, C., Liam, C.-K., Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y., Han, B., Chen, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv270 · Cited by 738
Self-citation

Flagged first, then by citations

Show all 30 references

1 of the 30 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–182 of 182

Analysis of real-word mutations of lung cancer driver genes in five regions of China
Sun, M., Guo, Y., Shao, G., Duan, X., Yang, Z., Zhang, P., Liu, Y., Dong, Y., Wang, X., Xu, Y., et al. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.10.28 · Cited by 8
The landscape of actionable genomic alterations in lung adenocarcinomas in India
Sharma, R., Kamireddy, A. P., Hussaini, S. M., Chatterjee, S., Hasan, Q. A., & Jain, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1256756 · Cited by 7
Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report
Luo, Z., Luo, C., Zhou, R., Xiao, Y., & Wang, T. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001523 · Cited by 7
Circulating tumor DNA – A potential aid in the management of chordomas
Frederico, S. C., Darling, C., Zhang, X., Huq, S., Agnihotri, S., Gardner, P. A., Snyderman, C. H., Wang, E. W., & Zenonos, G. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1016385 · Cited by 7
Self-citation
Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma
Li, X., Zhao, Z., Yi, S., Ma, L., Li, M., Liu, M., Zhang, Y., & Liu, G. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1561-0 · Cited by 7
All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations
Batra, U., Nathany, S., Mansi, S., Narayan, S., Jain, P., Dhanda, S., Jose, J. T., & Anurag, M. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04033-x · Cited by 8
Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort
Tankéré, P., Boidot, R., Bonniaud, P., Zouak, A., Foucher, P., Millière, A., Bertaut, A., Favier, L., Lagrange, A., Ghiringhelli, F., et al. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1924 · Cited by 7
Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations
Taniguchi, Y., Tamiya, A., Ishii, S., & Atagi, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy087 · Cited by 7
EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
Pan, H., Zhang, L., Meng, F., Guan, S., & Zhong, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1159308 · Cited by 6
Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
Li, G., Fang, M., Zhou, Y., Liu, X., Tian, P., & Mei, F.-J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20690 · Cited by 6
Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art
Fabrizio, F. P., Attili, I., & de Marinis, F. (2024) · Cancers · doi:10.3390/cancers16071331 · Cited by 6
Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family
Gabriel, L., McVeigh, T. P., MacMahon, S. W., Avila, Z., Donovan, L., Hunt, I., Draper, A., Minchom, A. R., Popat, S., Davidson, M., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107543 · Cited by 6
Epidermal growth factor receptor mutations in non–small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction–based assays
Shen, C., Ho, H., Yeh, Y., Chiu, C., & Chou, T. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000277 · Cited by 6
[Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC (2022 Version)].
(2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.101.47 · Cited by 6
Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review
Watanabe, N., Horio, Y., & Fujiwara, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-56 · Cited by 6
Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harboring uncommon EGFR mutations: a case report and literature review
Hakozaki, T., & Yomota, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s190034 · Cited by 6
Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: a case report
Ma, Y., Liu, H., Zhang, M., Liu, B., Ding, Q., Zhang, L., Guo, L., & Liu, M. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-321 · Cited by 6
Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns
Bai, R., Chen, X., Song, W., Tian, H., & Cui, J. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03840-y · Cited by 7
Probing phosphorylation events in biological membranes: The transducer function
Wirth, D., Özdemir, E., & Hristova, K. A. (2024) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2024.184362 · Cited by 5
Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
Lee, J. C., Hung, J., Kim, Y., Chang, G., Yoo, S. S., Yang, S.-H., Davis, K. L., Nagar, S. P., Taylor, A., Lee, S. Y., et al. (2021) · Asian Pacific Journal of Cancer Biology · doi:10.31557/apjcb.2021.6.2.123-132 · Cited by 5
Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches
Chang, C., & Chang, Y. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192114324 · Cited by 5
EGFR Mutation Detection in Brazilian Patients With Non–Small-Cell Lung Cancer: Lessons From Real-World Data Scenario of Molecular Testing
Montella, T. C., Zalis, M. G., Zukin, M., de Lima, V. C. C., Baldotto, C. S. D. R., Marchi, P. D., Salles, P. G. D. O., Mathias, C., Barrios, C. H., Kawamura, C., et al. (2023) · JCO Global Oncology · doi:10.1200/go.22.00426 · Cited by 5
Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon�21 L858R subsequent to treatment with EGFR‑TKIs
He, C., He, Y., Luo, H., Zhang, M., Wu, J., He, X., Fu, Y., Chen, W., & Zou, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10348 · Cited by 5
Application of targeted genome sequencing to brain metastasis from non-small cell lung carcinoma: Case report
Leclair, N. K., Calafiore, R., Wu, Q., Wolansky, L. J., & Bulsara, K. R. (2020) · Neurochirurgie · doi:10.1016/j.neuchi.2020.09.010 · Cited by 5
A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC
Chen, W., Hua, Y., Mao, D., Wu, H., Tan, M., Ma, W., Huang, X., Lu, J., Li, C., & Li, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722106 · Cited by 5
Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer
Yu, L., Wang, R., Zhao, Y., Wu, Y., Wang, L., Chen, H., He, Z., Wang, Q., & Wu, Y. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231168466 · Cited by 4
Self-citation
Distinct survival, optimal combination strategy of immunotherapy, and immunophenotype in uncommon and 20ins EGFR-mut lung adenocarcinoma: a multi-center study
Sun, Y., Xu, L., Deng, C., Du, X., Yu, Y., Yuan, H., Wang, H., Wang, X., Zhang, Y., & Chen, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00331-1 · Cited by 4
Self-citation
Establishing an 8‐gene immune prognostic model based on TP53 status for lung adenocarcinoma
Wu, G., Wang, Y., & Wan, Y. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24538 · Cited by 4
Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study
Qian, J., Ye, X., Huang, A., Qin, R., Cai, Y., Xue, Y., Zhang, S., Wang, W., Xiong, L., & Gu, A. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-507 · Cited by 3
Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer
Hm, H., wei, Y., Wang, J., Ran, F., Wen, Y., Chen, Q., & Bf, Z. (2022) · Balkan Journal of Medical Genetics · doi:10.2478/bjmg-2022-0015 · Cited by 4
Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data
Nagasundaram, N., & Guda, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1428158 · Cited by 4
Afatinib for the First-Line Treatment of EGFR Mutation-Positive NSCLC in China: a Review of Clinical Data
Tu, H., & Wu, Y.-L. L. C. (2020) · Future Oncology · doi:10.2217/fon-2020-0320 · Cited by 6
Self-citation
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
Zhang, B., Shi, C., Gao, Z., Zhong, H., Xiong, L., Gu, A., Wang, W., Chu, T., Zhang, W., Wang, H., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09409-3 · Cited by 4
Self-citation
Complex EGFR mutations in non-small cell lung cancer: a distinct entity?
Bieńkowski, M., Dziadziuszko, R., & Jassem, J. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-2022-05 · Cited by 2
Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies
Li, W., Bai, R., Guo, H., & Cui, J. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002548 · Cited by 4
[A Rare Case of Lung Adenocarcinoma with EGFR L833V/H835L Co-mutation and Literature Review].
Miao, Y., Wang, Y., Li, P., Tan, M., Wen, T., Wang, C., & Xie, S. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.36 · Cited by 3
[A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations].
Du, W., Wo, Y., Lu, T., Wang, Y., & Jiao, W. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.09.07 · Cited by 3
Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review
Zhao, Y., Zhai, L., Deng, L., Halmos, B., & Cheng, H. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.017 · Cited by 3
In Regard to “Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations”
Caliman, E., Petreni, P., Brugia, M., Antonuzzo, L., & Mazzoni, F. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.002 · Cited by 3
Druggable driver gene alterations in redefined large cell carcinoma in Chinese patients: an observational study
Yang, J., Li, Y., Ma, B., Xie, H., Chen, L., Gao, X., & He, W. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1675 · Cited by 1
Self-citation
Diffusion kernel-based predictive modeling of KRAS dependency in KRAS wild type cancer cell lines
Ulmer, B., Odenthal, M., Buettner, R., Roth, W., & Kloth, M. T. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-021-00211-8 · Cited by 2
Prognostic implications of uncommon EGFR exon 19 deletion-insertion mutations in non-small cell lung cancer treated with third-generation EGFR-TKIs
Zhang, R., Yan, H., Tian, F., Jiang, Y., Chen, Y., Huang, J., Ruan, Z., Xu, S., Huang, Z., Xu, Q., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108755 · Cited by 2
Self-citation
Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex Mutation
Simionato, F., Calvetti, L., Cosci, M., Scarparo, S., & Aprile, G. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s280933 · Cited by 2
Osimertinib in uncommon EGFR exon 21 L861R and EGFR exon 18 deletion-insertion mutant non-small cell lung cancer—case report
Wang, Y., Dorwal, P., Rajadurai, S., & Arulananda, S. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-788 · Cited by 2
Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors
Liu, X., Stamboulian, M. H., Borgeaud, M., Zhu, E., Weipert, C. M., Zhang, N., Nilsson, M. B., Wang, K., Hong, L., Wang, J., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103948 · Cited by 2
Self-citation
Determinación de mutaciones (del E746-A750 exón 19 y L858R exón 21) en el gen receptor del factor de crecimiento epidérmico (EGFR) en muestras de suero y biopsia de carcinoma pulmonar no microcítico (CPNM)
Castro-Valencia, K., González-Herrera, L. J., Muñoz-Santos, E., López-González, P., Sosa–Escalante, J. E., Pérez‐Mendoza, G., & Medina‐Escobedo, G. (2018) · REVISTA BIOMÉDICA · doi:10.32776/revbiomed.v29i3.622 · Cited by 1
An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report
Falla-Martinez, J., Espinosa, D. M., Baena, J. C., Rodriguez, L. X., Sua, L. F., & Zambrano, A. R. (2019) · Journal of Medical Case Reports · doi:10.1186/s13256-019-2075-y · Cited by 1
Ultra-rapid Idylla™ EGFR mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer
Qiu, T., Zhang, F., Zheng, B. J., Feng, Z., Li, W., Hua, Z., Chu, L., & Ying, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1064487 · Cited by 1
Molecular profiling of patients with advanced lung adenocarcinoma diagnosed between 2015 and 2020 in French Polynesia
Messekher, M., François, H., Denis, M. G., Ferrer-Lopez, P., Bost‐Bezeaud, F., Mazières, J., & Parrat, É. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.101059 · Cited by 1
To establish a prognostic model of epidermal growth factor receptor mutated non-small cell lung cancer patients based on Least Absolute Shrinkage and Selection Operator regression
Li, B., & Zhang, X. (2023) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000865 · Cited by 1
Self-citation
EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non–Small-Cell Lung Cancer
Giustini, N., Pritchard, C. C., Kamat, N. V., & Menon, M. P. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00215 · Cited by 1
Efficacy and Safety of Chemotherapy or EGFR ‐ TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
Liao, C., Bai, L., He, T., Liang, Q., Hu, D., Lei, S., He, Y., & Wang, Y. (2024) · Cancer Medicine · doi:10.1002/cam4.70542 · Cited by 1
Characteristics of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation
Sonoda, D., Kondo, Y., Maruyama, R., Mitsuhashi, S., Tamagawa, S., Naito, M., Mikubo, M., Shiomi, K., & Satoh, Y. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18143-6 · Cited by 1
Medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms
Leipert, J., Hammerschmidt, S., & Geßner, C. (2019) · Der Pneumologe · doi:10.1007/s10405-019-00284-7 · Cited by 1
An Elderly Case of Lung Adenocarcinoma with an Epidermal Growth Factor Receptor Gene L861Q Mutation Which Was Successfully Treated with Osimertinib
Kato, Y., Kato, T., Tanaka, H., Kajikawa, S., Yonezawa, T., Yamamoto, Y., Tsuzuki, T., Yamaguchi, E., Kubo, A., & Ito, S. (2020) · Haigan · doi:10.2482/haigan.60.411 · Cited by 1
Limited effect of afatinib in a non‐small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report
Tamura, T., Kawakado, K., Makimoto, G., Nakanishi, M., & Kuyama, S. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13941
Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
Lin, R., Chen, R., Chen, Z., Hu, L., Guo, W., Zhang, Z., Lin, L., & Chen, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731572 · Cited by 1
Self-citation
Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Marcoux, N., & Sequist, L. V. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00007-9
Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation
McAuliffe, A., Bindal, P., Haley, M., & Vredenburgh, J. J. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219829810
[Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
Zhou, W., Zhang, W., & Han, B. (2020) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2020.02.07
Outcomes of Afatinib in Non-small Cell Lung Cancer Patients Harboring Uncommon Epidermal Growth Factor Receptor MutationsPreprint
Zhao, K., Hu, S., Wei, D., Chen, W., Song, Y., & Wang, C. (2020) · doi:10.21203/rs.3.rs-67709/v1
EGFR L858R Mutation Combined with EGFR Exon 20 Insertion Mutation in Lung Adenocarcinoma: A Case Report and Literature Review
朱, 文. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111792
The broad spectrum of tyrosine kinase inhibitors. Treatment of a rare EGFR R776H mutation with Osimertinib: Case report
Cui, J., Tabbara, S. O., & Chadha, J. S. (2023) · SAGE Open Medical Case Reports · doi:10.1177/2050313x231196663
Liquid Biopsy
Ciaccio, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-24958-7_34
Clinical features and outcomes of unresectable locally advanced non-small cell lung cancer with uncommon EGFR Mutations: A retrospective multi-center Chinese studyPreprint
Xu, K., Zheng, X., Chen, M., Mingyan, E., Zhang, L., Cao, J., Zhang, X., Ding, X., Xia, B., Zhao, L., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4130244/v1
Self-citation
A Comprehensive Review of Epidermal Growth Factor Receptor Mutation Abundance in Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors
Zeng, L., Dai, Y., Liu, Y., Song, B., Lin, H., & Jianhong, X. (2024) · Oncology Research and Treatment · doi:10.1159/000541520
Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR-mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors
Lee, P.-H., Hsiao, Y.-C., Huang, Y.-H., Hsu, K.-H., Tseng, J., Lin, H., Chang, G., & Yang, T. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001762
ASO Author Reflections: Impact of the Epidermal Growth Factor Receptor Exon 20 Q787Q Mutation on the Clinical Course of Non-Small-Cell Lung Cancer
Sonoda, D., Kondo, Y., Maruyama, R., Mitsuhashi, S., Tamagawa, S., Naito, M., Mikubo, M., Shiomi, K., & Satoh, Y. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18270-0
Conformational Dynamics of Wild‐Type to Triple Mutant EGFR‐TKD Captured by Coarse‐Grained Simulations
Mir, S. A., Maharana, S. R., Mahapatra, K., Alamri, A., Khan, M. S., Ahmad, I., Meher, R., & Nayak, B. (2025) · ChemistrySelect · doi:10.1002/slct.202501229
Additional file 4 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915426
Additional file 2 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915417
Additional file 1 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915414
Additional file 3 of Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19915420
Additional file 3 of Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
Park, S., Lee, S. Y., Kim, D., Sim, Y. S., Ryu, J.-S., Choi, J., Lee, S. H., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2021) · Figshare · doi:10.6084/m9.figshare.13559875
Additional file 2 of Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
Park, S., Lee, S. Y., Kim, D., Sim, Y. S., Ryu, J.-S., Choi, J., Lee, S. H., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2021) · Figshare · doi:10.6084/m9.figshare.13559872
Additional file 1 of Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
Park, S., Lee, S. Y., Kim, D., Sim, Y. S., Ryu, J.-S., Choi, J., Lee, S. H., Ryu, Y. J., Lee, J. H., & Chang, J. H. (2021) · Figshare · doi:10.6084/m9.figshare.13559869
EGFR p. V774M /p. the S768I Compound Mutation in NSCLC Is a Good Prognostic Marker for IPHC ‐ and Furmonertinib‐Based Treatment: A Case Report
Wang, Y., Ren, G., Song, Z., Hu, L., Li, W., & Wang, X. (2025) · Cancer Reports · doi:10.1002/cnr2.70444
Mechanism of afatinib resistance in non-small cell lung cancer patients with nonclassical EGFR mutations: A multicenter, retrospective study
Wu, R., Fang, S., Zhang, Y., Zhou, T., Yin, J., Yao, Y., Ding, M., Ding, H., Wang, J., Zhang, Q., et al. (2026) · Medicine · doi:10.1097/md.0000000000049283
Epidermal growth factor receptor dysregulation and climate change: insights into pollution-promoted lung cancer
Nikaido-Landry, T., Zhang, Y., & Lim, E. L. (2026) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2024.0508 · Cited by 1
Structure-based virtual screening, multi-score docking, and molecular dynamics simulation of novel small molecules targeting the epidermal growth factor receptor for potential management of oral squamous cell carcinoma
Azmi, M. B., Zia, T., Asif, U., Sehgal, S. A., Naeem, S., Qureshi, S. A., Ahmed, S. D. H., & Imtiaz, F. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00722-4
Osimertinib in advanced non-small cell lung cancer (NSCLC) harboring different EGFR uncommon variants: real-world data from the Italian biomarker ATLAS database
Farinea, G., Mogavero, A., Vitale, A., Roca, E., Scotti, V., Delmonte, A., Veccia, A., Reale, M. L., Bironzo, P., Genova, C., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108369
EGFR exon 20-altered NSCLC in China: molecular heterogeneity and real-world outcomes with sunvozertinib
Zhang, J., Cui, Y., Ren, Q., Wu, X., Li, J., Liu, X., Zhang, B., & Yue, D. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04583-3

Authors: Tu, H.-Y., Ke, E.-E., Yang, J.-J., Sun, Y.-L., Yan, H.-H., Zheng, M.-Y., Bai, X.-Y., Wang, Z., Su, J., Chen, Z.-H., Zhang, X.-C., Dong, Z.-Y., Wu, S.-P., Jiang, B.-Y., Chen, H.-J., Wang, B.-C., Xu, C.-R., Zhou, Q., Mei, P., Luo, D.-L., Zhong, W.-Z., Yang, X.-N., & Wu, Y.-L.
Affiliations: Guangdong General Hospital (CN)
Southern Medical University (CN)
Corresponding author: Wu, Yi-Long
ORCID: Tu, Hai-Yan
Yang, Jin-Ji
Sun, Yue-Li
Yan, Hong-Hong
Zheng, Ming-Ying
Su, Jian
Zhang, Xu-Chao
Dong, Zhong-Yi
Wu, Si-Pei
Jiang, Ben-Yuan
Chen, Hua-Jun
Xu, Chong-Rui
Zhou, Qing
Mei, Ping
Zhong, Wen-zhao
Yang, Xue-Ning
Wu, Yi-Long
Venue: Lung Cancer
Publisher: Elsevier BV
Published: 2017-12
Volume: 114
Pages: 96-102
ISSN: 0169-5002 (ISSN-L)
DOI: 10.1016/j.lungcan.2017.11.005
OpenAlex: W2768053061
Cited by: 182
References: 30
Citations by year: 2026: 6 · 2025: 8 · 2024: 13 · 2023: 19 · 2022: 30 · 2021: 25 · 2020: 42 · 2019: 26 · 2018: 13
FWCI: 18.39
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Lung Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: Hangzhou Science and Technology Bureau (2014Y2-00050, 201402031)
National Health and Family Planning Commission of the People's Republic of China (2014Y2-00050, 201402031)
National Key Research and Development Program of China (2014Y2-00050, 201402031)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: EGFR mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, exon 20 insertion, G719X mutation, T790M mutation, progression-free survival, treatment response, smoking, Chinese patients
MeSH terms: Erlotinib Hydrochloride, Gefitinib, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Exons, Female, Genotype, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Predictive Value of Tests, Quinazolines, Retrospective Studies, Smoking, Disease-Free Survival, Asian People, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks